BMT CTN Protocol 1706/SWOG S1803 MM Maintenance

Phase III Study of Daratumumab (NSC- 791647) + Lenalidomide (LD) or Lenalidomide (L) as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

Below are protocol-related documents, which may be periodically updated.

  • Protocol, dated June 27, 2019
  • Key Personnel

             BMT CTN Chair: Parameswaran Hari, MD, MRCP

             SWOG Protocol Coordinator: Cynthia Smith

For the SWOG S1803 / BMT CTN 1706 study, the BMT CTN is endorsing the study and providing accrual credit. Centers participate via their NCTN group. BMT CTN Centers will receive both NCTN and BMT CTN accrual credits. The protocol may be accessed through the CTSU website: For questions about the study and how to participate, contact the SWOG protocol coordinator, Cynthia Smith, at or the CTSU Help Desk at or 1 888 823-5923.